Billing and Coding: MolDX: Minimal Residual Disease Testing for Solid Tumor Cancers (A58454) - R19 - Effective April 6, 2026

Date Posted: August 8, 2026

This Billing and Coding Article has been revised under contract numbers: 02101 (AK), 02201 (ID), 02301 (OR), 02401 (WA), 03101 (AZ), 03201 (MT), 03301 (ND), 03401 (SD), 03501 (UT), and 03601 (WY).

Effective Date: April 6, 2026

Summary of Changes:

Under Article Text subheading Additional Test-specific Indications, Limitations and Instructions revised 1st sentence to read "neoadjuvant breast cancers (Signatera and NeXT Personal)". Formatting was corrected throughout the article. This revision is due to a new covered test that has successfully completed a TA and is effective for 04/06/2026.

Visit the Noridian Molecular Diagnostic Services webpage to view the Active MolDX LCDs or access it via the CMS MCD.

Last Updated Aug 06 , 2026